Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
Authors:
- Marie WislezMWMarie Wislez
- Martine AntoineMAMartine Antoine
- Laurence BaudrinLBLaurence Baudrin
- Virginie PoulotVPVirginie Poulot
- Agnes NeuvilleANAgnes Neuville
- Maryvonne PradereMPMaryvonne Pradere
- Elisabeth LongchamptELElisabeth Longchampt
- Sylvie Isaac-SibilleSISylvie Isaac-Sibille
- Marie-Paule LebitasyMLMarie-Paule Lebitasy
- Jacques CadranelJCJacques Cadranel
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 68 (2) , 185-191
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Immunohistochemical expression of TTF‐1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneityPathology International, 2007
- Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar FeaturesThe Journal of Molecular Diagnostics, 2007
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of DiseasesJournal of Thoracic Oncology, 2006
- Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic FeaturesClinical Cancer Research, 2006
- Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lungJournal of Clinical Pathology, 2005
- Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and OpportunitiesJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004